Page 5 - பதிவு அறிக்கைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பதிவு அறிக்கைகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பதிவு அறிக்கைகள் Today - Breaking & Trending Today

Purple Biotech : NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors (Form 6-K)


Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer
REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the tr ....

United States , South Korea , Gil Efron , Bertrandc Liang , Megan Humphreys , Alberto Bessudo , Chuck Padala , Exchange Commission , Company Contact , Purple Biotech Ltd , California Cancer Associates For Research Excellence , Drug Administration , Bristol Myers Squibb , Coeptis Pharmaceuticals , Minimal Adverse Events , Initial Clinical Data , Ongoing Phase , Advanced Solid , Response Observed , Refractory Gastroesophageal Junction , Purple Biotech , California Cancer Associates , Chief Medical Officer , Burke Therapeutics , Looking Statements , Safe Harbor ,

CreditRiskMonitor Announces First Quarter Results


CreditRiskMonitor Announces First Quarter Results
ACCESSWIRE
15 May 2021, 06:05 GMT+10
VALLEY COTTAGE, NY / ACCESSWIRE / May 14, 2021 / CreditRiskMonitor (OTCQX:CRMZ) reported that revenues for the quarter ended March 31, 2021 increased to $4.13 million up 11% from $3.71 million in 2020. The Company reported a reduction in operating expenses of approximately $102,600 or 2.5% as compared to 2020, primarily driven by a revised methodology of accruing commissions implemented in December 2020. The Company reported a pre-tax income of approximately $243,000 as compared to pre-tax loss of approximately $264,200 in the prior year.
Mike Flum, President & COO, said, We continue to reinvest in our service with new product development, additional data acquisition, and employee retention. We remain committed to enhancing the value proposition of our services and expanding our staff to support the financial risk analysis needs of our customer base. We continue to press forward ....

Mike Flum , Exchange Commission , Company Registration Statements Or Securities , Private Securities Litigation Reform Act , Registration Statements , United States Wire Group , பரிமாற்றம் தரகு , நிறுவனம் பதிவு அறிக்கைகள் அல்லது பத்திரங்கள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , பதிவு அறிக்கைகள் , ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு ,